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platinum-based agents 20.3%, UFUR 8.3%, taxanes 7.7%, etoposide 7.5%). Close to 
three quarters (74.8%) of treated patients received combination therapy with plat-
inum-based agents. Of 1,221 patients treated with platinum-based combination 
therapy, the therapy most commonly used includes gemcitabine (37.5%), taxanes 
(21.5%), and vinorelbine (18.2%), while 21.4% of patients received two or more other 
agents. We observed longer median survival in patients with a higher number of 
chemotherapy agents received. ConClusions: Lung cancer patients in Taiwan 
incurred considerable health care costs after diagnosis. More than half of patients 
were treated with chemotherapy, in particular with multiple chemotherapy agents. 
Future research comparing cost-effectiveness among different treatment options 
is warranted.
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objeCtives: This work aimed to develop rigorous models of the Australian costs of 
four common chemotherapy adverse event (diarrhoea, vomiting, anaemia and neu-
tropenia), which provide standard cost estimates and can be used in future models 
of chemotherapy cost effectiveness. Methods: Decision analytic modelling was 
used to identify the costs and consequences of AEs. These are not only stand alone 
models, but also form decision tree sections to be incorporated into larger models 
of chemotherapy cost effectiveness. Model structures are based on best-practice 
clinical pathways, and incorporate efficacy of side effect treatment, quality of life 
and chemotherapy dose. Literature reviews identified clinical inputs. Costs of treat-
ment were obtained from standard Australian sources such as the Pharmaceutical 
Benefits Schedule. The perspective was the Australian health care system. One-way 
sensitivity analyses explored uncertainty in the models. Results: The base case 
average cost per patient of diarrhoea ranged from $19 (mild AE) to $4,821 (severe AE); 
those for anaemia ranged from $51 (mild AE) to $17,100 (moderate AE) depending on 
the type of chemotherapy and anaemia treatment. Vomiting prevention base case 
costs ranged from $0.84 (low risk chemotherapy) to $157.55 (high risk chemotherapy 
requiring breakthrough and refractory management). Neutropenia base case costs 
ranged from $2,235 (outpatient management) to $12,054 (intensive care required). 
Where possible, the impact on quality of life and chemotherapy total dose was also 
modelled. Estimates of AE costs vary widely in the literature, however our estimates 
appear consistent with studies of similar methodology. ConClusions: The four 
models presented represent best-practice modelling techniques for chemotherapy 
AEs. Each has been designed to enable either the results or the model structure to 
be incorporated into larger models of chemotherapy cost effectiveness. This allows 
model builders to incorporate rigorous, Australian-specific estimates of the costs and 
consequences of chemotherapy AEs into models of chemotherapy cost effectiveness.
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objeCtives: To estimate direct medical costs and productivity costs of hormonal 
receptor positive, HER2 negative metastatic breast cancer (MBC HR+ HER2-) under 
the public health care system (SUS) and societal perspectives in Brazil, being MBC 
cost data very scarce in Brazil so far. Methods: A systematic literature review was 
performed in the following databases: Cochrane, MEDLINE via Pubmed, LILACS, 
EMBASE and CRD until FEB 2013. Gray literature was also included. National guide-
lines search and expert validation was carried out specifically for the direct medical 
cost estimations. Direct medical costs were stratified as pre and post-progression 
costs and terminal costs. Pre and post-progression costs considered outpatient, 
inpatient and monitoring costs. For post-progression, metastasis treatment costs 
were also estimated, including bone, lung, liver and brain metastasis. For the pro-
ductivity costs, the Human Capital method was chosen. Days of absenteeism were 
obtained from the literature and a Markov model was used to estimate the loss of 
productivity in 1 year (as the mean age of MBC in Brazil is 59 and official retirement 
at 60 years of age). Unit costs were obtained from Brazilian official lists and IBGE 
(income). All costs are expressed in 2012 Brazilian Real (BRL). Results: Pre, post-
progression and terminal costs of MBC HR+HER2-were estimated in BRL308, BRL731 
and BRL4.164 respectively, under SUS perspective. Post-progression metastasis treat-
ment costs presented an average of BRL12.047 under SUS perspective. The productiv-
ity costs were estimated in BRL26.056 under the societal perspective considering 
the available treatments at SUS for MBC HR+HER2- patients. ConClusions: MBC 
HR+HER2- post-progression costs impose a significant economic burden under SUS 
perspective as well as productivity losses to the society. Novel therapies that post-
pone progression in those patients may reduce costs associated.
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objeCtives: Very limited data is available on the cost and burden of HPV-related 
diseases in Turkey. The aim of our analysis is to evaluate the corresponding cost 
through understanding the current clinical practices, use of resources and treat-
in the USA in 2002. Inpatient care costs accounted for more than 60% of total 
cost. ConClusions: Although the economic impact of the VTE in cancer patients 
as well as the impact of VTE on patients’ quality of life is not well studied, the 
present review demonstrate that there is a substantial humanistic and economic 
burden associated with VTE in cancer patients.
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objeCtives: Febrile neutropenia (FN) is a potentially life-threatening complica-
tion of chemotherapy which generally prompts immediate hospitalisation. The 
study objective was to evaluate the resource use and cost of hospitalisation for 
FN within the Irish Health care setting. Micro-costing techniques were used. The 
health payer perspective was adopted. Methods: This was a single centre study. 
Adult cancer patients undergoing chemotherapy, who were subsequently admit-
ted for FN, were identified prospectively. Patient medical records were reviewed 
retrospectively. Results: Patient demographics and resource utilisation data (per-
taining to the management of FN) were obtained from a cohort of 32 patients (69% 
female, mean age = 58.8 years). Twenty-five percent of patients had more than one 
FN episode. In total, 42 FN episodes were captured; 60% of episodes had occurred 
within the first two cycles of chemotherapy. The bootstrap estimation was used to 
determine mean hospital length of stay (LOS) with standard deviation (± SD) and 
mean costs (± SD). The mean LOS was 7.3 (± 0.5) days. The mean cost per FN episode 
was € 8,915 (± 718). The major cost driver was hospital bed-stay (mean cost of € 6,851 
(± 549)). Other cost drivers included antibacterial treatment at € 760 (± 156), labora-
tory investigations at € 538 (± 47) and the requirement for blood bank products at 
€ 525 (± 189). ConClusions: To our knowledge, this is the first investigation of the 
cost of chemotherapy induced FN within the context of the Irish Health care setting. 
Our results will be used in cost-effectiveness analyses of novel chemotherapeutic 
agents and interventions which prevent or treat FN.
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Though lung cancer, and the most common subtype, non-small cell lung cancer 
(NSCLC), occur frequently, there are limited data quantifying the economic burden 
of these cancers in Europe.objeCtives: To describe the burden of NSCLC in three 
European countries using patient-level data from commercially available health 
care data. Methods: Patient-level data were obtained for France from the PMSI 
(French National discharge database; containing data from publicly-funded hos-
pitals) from 2008 to 2011 while excluding patients with a prior-hospitalization for 
lung cancer in the preceding 24-month period (2006-2007). As NSCLC does not have 
a separate ICD-10 code, expert opinion was used to eliminate patients diagnosed 
with non-NSCLC, based on particular procedures and tests. Hospital resource 
use was valued using French DRG tariffs. Chemotherapy regimens were valued 
using official rates. Results: A total of 61,144 patients were identified with lung 
cancer in 2008. 19,099 were excluded because of prior lung cancer diagnoses. Of 
this cohort of 42,043 patients, 25,054 were exclusively treated in the public setting; 
15,061 were identified as NSCLC and were considered in this analysis. Hospital-
related costs cumulated over the follow-up period were estimated at € 337,382m, 
with chemotherapy costs representing 9%. Mean cumulated hospital-related 
cost per-patient were estimated at € 22,401 over the follow-up period. Terminal 
care represented a mean per-patient cost of € 10,440. Adverse events triggering 
hospital-expenses represented a mean per-patient cost of € 5,694. Patients ≤ 55 
years incurred higher costs per-person over the follow-up period than patients > 55 
years; € 25,386 vs. € 21,368. These extra costs were mostly driven by chemotherapy 
costs(€ 13,287 vs. € 10,561). Patient with metastases incurred higher costs over the 
follow-up period than patients without these, € 23,118 vs. € 21,934. ConClusions: 
This is one of the first analyses quantifying the economic burden of NSCLC. The 
burden for France is substantial. Subsequent analyses will allow for comparisons 
of this burden across other countries.
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objeCtives: To examine chemotherapy treatment patterns, health care costs, 
and mortality of lung cancer patients in Taiwan. Methods: This study analyzed 
medical and pharmacy claims from a random sample of one million taken from 
all beneficiaries covered under Taiwan’s national health insurance in 2000. Newly 
diagnosed lung cancer patients between 2000 and 2008 (first observed diagnosis as 
the index date) were identified based on medical claims with associated diagnoses. 
Patients were followed until death or the end of 2008. Per patient per month [PPPM] 
total health care costs (in USD) and median survival were reported. Chemotherapy 
treatment patterns during the follow-up were examined. Results: This study 
included 3,343 lung cancer patients (mean age: 67.1 years; 34.5% female; 35.4% 
secondary lung cancer). Median survival was 8.1 months. PPPM costs were $2,322 
USD (interquartile range $450-$2,902). Lifetime costs from diagnosis among those 
who died during the study period were $12,788 USD (interquartile range $2,674-
$17,546). Of the 1,633 patients who received chemotherapy during the follow-up, 
375 received only one chemotherapy agent (gemcitabine 35.7%, vinorelbine 20.5%, 
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objeCtives: FN can be a serious complication of CHT, increasing mortality risk 
and health care costs. Incidence and inpatient hospital costs of FN in Switzerland 
are currently not reported; therefore this study aimed to: 1. Estimate the number 
of FN-related hospitalizations. 2. Assess inpatient hospital costs per FN event in 
Switzerland. Methods: The main data source was MedStat, a comprehensive data-
base of all Swiss hospitalizations from 1997-2010. BC and NHL cases were identified 
from ICD-10-GM codes. Hospitalizations for FN were identified by a simultaneous code 
of BC or NHL and neutropenia. Incident cases of cancer were identified as patients 
treated in 2010 for the first time since 2002. Results were compared to data from the 
Foundation National Institute for Cancer Epidemiology and Registration (NICER). Cost 
data stems from the cantonal hospital of Winterthur. Results: Using MedStat data, 
645 male and 557 female NHL patients and 6’391 female BC patients were hospital-
ized in 2010 for the first time. Corresponding annual incidence data from NICER were 
780 male and 688 female NHL patients and 5’388 female BC patients. The proportion 
of hospitalizations due to FN was 8.2% (190/2’311) among male and 6.0% (123/2’063) 
among female NHL patients, and was 2.6% (255/9’650) among female BC patients. 
In-hospital mortality of FN cases was 9.5% for men and 5.7% for women with NHL, 
and 4.3% for BC. Median inpatient treatment costs for an FN event were CHF 8’399 
(mean: CHF 14’006) in NHL and CHF 4’208 (mean: CHF 10’020) in BC. Nursing time was 
the most important cost component and length of stay was the most important driver 
of total inpatient cost. ConClusions: 3% to 8% of all hospitalizations in NHL and 
BC patients were due to FN. Our results suggest that FN leads to considerable risk of 
death and incurs high in-hospital care cost in Switzerland.
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objeCtives: To compare annual management costs of castration-resistant prostate 
cancer (CRPC) patients at high risk of developing bone metastases (BM) versus those 
that already had BM in Spain. Methods: An expert panel of 5 urologists and 3 oncol-
ogists from Spanish health centres was asked to estimate the mean annual resource 
use in the management of non-metastatic CRPC patients and in the first, second and 
subsequent years after developing BM. Hospital resources were stratified into four 
major categories: 1) general resources [medical visits, diagnostic and monitoring pro-
cedures, hospital admission and surgeries], 2) hormone therapy, 3) chemotherapy and 
4) analgesic treatments. The last three categories included: drug costs, adverse event 
(AE) management-costs and pre-medication costs. Skeletal-related events (pathologi-
cal fracture, radiation or surgery to bone and spinal cord compression) often suffered 
by BM patients were excluded from the analysis as Spanish cost-related data had 
recently been published. Unit costs (€ , 2013) for each identified resource were obtained 
from a national cost-database. Results: Total management-related annual costs for 
non-metastatic CRPC patients were € 2,691.57; € 978.51 were hormone therapy drug 
costs, € 11.10 analgesics costs and € 243.55 AE management costs. No chemotherapy 
was administered in these patients. Annual management cost for BM patients was 
€ 6,000.37 the first year, € 14,468.35 the second year and € 14,313.87 in subsequent years. 
Hormone therapy drug costs accounted for € 946.67, € 948.13 and € 948.13 in the first, 
second and subsequent years, while chemotherapy costs accounted for € 1,892.21 
(32.2%); 9,485.41 (66.2%) and € 9,143.92 (64.4%), respectively. Analgesic costs increased 
from € 597.29 (first year) to € 915.16 and € 1,031.20 (second and subsequent years) and 
AE management costs increased from € 595.63 (first year) to € 758.58 (second year) 
and € 732.14 (subsequent years). ConClusions: CRPC patients with BM had higher 
management costs than non-metastatic patients especially after the first year of 
treatment, which was mainly due to chemotherapy drug costs.
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objeCtives: Little is known about costs of managing adverse events (AEs) associ-
ated with currently-available therapies in advanced melanoma. This study identi-
fies and estimates the costs of these AEs in France (FR), Italy (IT), The Netherlands 
(NL), and Spain (ES). Methods: A comprehensive literature search was conducted 
to identify common grade 3/4 AEs from product labels and published phase II/III 
advanced melanoma studies in PubMed, conference abstracts, and European treat-
ment guidelines. Resource utilizations for the management of each type of AE in typ-
ical inpatient/outpatient treatment setting were determined via in-depth interviews 
with 5 melanoma clinicians in each country. Outpatient and inpatient 2012 costs 
were then estimated for each type of AE by applying country-specific tariffs, except 
in Spain where costs were obtained from government database or best published 
sources. Results: Most frequent grade 3/4 AEs associated with chemotherapies 
included neutropenia, vomiting, and anemia. Vemurafenib was commonly associ-
ated with cutaneous squamous cell carcinoma (CSCC)/keratoacanthoma, rash, and 
ment algorithms based on expert opinion. Methods: This study uses the Delphi 
method to reach experts’ consensus on the clinical practices currently being used 
in Turkey. Delphi method has been widely used in medical areas where empirical 
data is scarce. The survey developed for this study includes questions to under-
stand the clinical resource use in order to calculate the associated costs. Although 
the panelists’ answers are unlikely to change after the second iteration accord-
ing to the literature, a three-iteration panel was needed to reach a consensus in 
practice. The consensus is then used to calculate the cost of an episode of care for 
genital warts (GW), CIN 1, CIN 2/3, different cervical cancer stages from the payer’s 
perspective. Results: TDP-HPV included a total of 10 experts, including gyneco-
oncologists, dermatologists and a medical oncologist. The cost of a GW episode of 
care is approximately USD 263.58 to the government. CIN 1 cases are only treated if 
the disease persists for 2 years, which happens in about 5% of cases. The cost of a 
CIN 1, CIN 2/3 episode of care is calculated as USD 127, USD 262 to the government, 
respectively. The cervical cancer (CC) stages are divided into local CC, regional CC, 
and distant CC. The costs associated with these states are USD 1,340, USD 4,345, 
and USD 8,150. ConClusions: Early diagnosis and treatment is crucial from the 
cost perspective too as a more severe disease costs more. GWs are sometimes left 
out when HPV-related diseases are considered. However, this study mentions that 
GW presents a serious burden to the society.
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objeCtives: EVE in association with aromatase inhibitor was recently approved 
by ANVISA (Brazilian Regulatory Agency) for MBC-HR+ patients. EVE redefines the 
role of endocrine therapy in MBC-HR+ reversing endocrine resistance. The aim of 
this study is to determine the costs associated to the introduction of EVE + EXE for 
the Brazilian private system population. Methods: A previous study from real-
world (RW) data between 2011-12 (large private database of medical claims for 
chemotherapy (CT), Evidencias Database) and published data identified MBC-HR+ 
patients and evaluated costs of treatments and adverse events (AEs), by a micro-
costing approach. Patients were divided into three groups, according to metastasis: 
bone exclusive (B), Visceral exclusive (V) and Bone plus Visceral (BV). For this study 
the financial impact of the adoption of EVE+EXE was calculated in this population, 
based on the previous findings. Direct medical costs of EVE, hormones, CT, hospi-
talization, supportive care, radiation, monitoring and AEs were considered. A cohort 
of 100 patients with MBC-HR+ was simulated in a decision tree to obtain the costs 
for each group and the mean cost/ patient. Costs were estimated in 2013 Brazilian 
Real (R$). Results: RW data showed the following distribution of patients: B 38%, 
V 42% BV 20%. Lengths of treatment (months) were B 25.1-30, V 16.1; BV 14-19.6. 
Mean costs/patient/group, before EVE+EXE adoptions, were B R$135.744 (US$67,872), 
V R$129.079 (US$64,539) and BV R$117.172 (US$58,568). If EVE+EXE substituted 80% 
or 50% of the current treatments, the incremental percentage of costs would be B 
(5%; - 9%), V (5,7%; -16%) and BV (22%; 14%). Costs with AEs were at least 50% lower 
with the use of EVE+EXE. ConClusions: EVE adoption in association with EXE 
may be cost saving for some groups of MBC-HR+ patients. For other groups, the 
incremental cost is not superior to 22%.
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objeCtives: To assess the cost of HER2-positive (HER2+) metastatic breast cancer 
(mBC) for patients initiating an oral anticancer treatment (OAT) from the perspective 
of the French National Health Insurance (NHI). Methods:  A prospective observa-
tional multicenter study was conducted among 284 HER2+ mBC patients treated by 
68 oncologists initiating a treatment containing an OAT between March 2011 and 
February 2012. Costs data were available for 199 patients. Clinical characteristics, 
treatment patterns, quality-of-life, adherence and health care resources data were 
collected. Health care resource use data on hospitalization, medical consultation, 
drug and radiation-therapy were reported by oncologists at treatment initiation and 
after each 3-month period during a 9 months maximum period. Cost estimations 
were based on unit costs from national databases (French Diagnosis Related Group 
cost database and NHI database for drug unit cost). Results: A total of 109 patients 
(55%) received an OAT only and 90 (45%) received oral and intravenous (IV) drugs. 
Thirty patients (15%) were treated with radiation therapy and 43 patients (22%) 
with hormonal-therapy in addition to chemotherapy. The overall average cost of 
management per patient was 28,482€ ± 14,914 for all patients, 19,412€ ± 9,462 for 
patients with an OAT only and 39,467€ ± 12,770 for patients with oral and IV drugs. 
Drug costs were 27,669 € ± 14,976 and they represented 97% of the total hospital cost 
of management (hospitalizations, consultations and drugs). ConClusions: This 
prospective observational study conducted among HER2+ mBC patients shows that 
the route of drug administration has an impact on treatment costs. Nevertheless, 
the study design does not allow concluding that OAT were associated with lower 
costs and cost savings. These finding however warrants further exploration within 
the context of micro-costing studies from the hospital and community perspective 
in order to better understand the health care resources used that are required to 
manage patients treated with OAT.
